[25], our study showcased that the pyrotinib-containing regimen was ≤ 2 line treatment could achieve significantly better PFS than that of those with >2 line treatment (9.6 vs 7.5 months, p = .001), advising for HER2-positive BC patients with BM, pyrotinib-containing treatment should be given early. The gene discussed is ERBB2; the disease is breast cancer.